• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

作者信息

Yuan Yin, Lane Steven W

机构信息

The Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, and Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.

Cancer Research Program, QIMR Berghofer Medical Research institute, Cancer Care Services, Metro North Health, Brisbane.

出版信息

Haematologica. 2025 Apr 1;110(4):825-827. doi: 10.3324/haematol.2024.285414. Epub 2025 Mar 19.

DOI:10.3324/haematol.2024.285414
PMID:40165732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959264/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8db/11959264/97e93a5a19a0/110825.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8db/11959264/97e93a5a19a0/110825.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8db/11959264/97e93a5a19a0/110825.fig1.jpg

相似文献

1
Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.骨髓增殖性肿瘤的预防、诊断与管理：综述系列介绍
Haematologica. 2025 Apr 1;110(4):825-827. doi: 10.3324/haematol.2024.285414. Epub 2025 Mar 19.
2
Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH).骨髓增殖性肿瘤、肥大细胞增多症和骨髓增生异常/骨髓增殖性肿瘤的细胞遗传学管理：来自法语血液细胞遗传学组（GFCH）的指南。
Curr Res Transl Med. 2023 Oct-Dec;71(4):103424. doi: 10.1016/j.retram.2023.103424. Epub 2023 Oct 20.
3
Introduction to a review series on classic myeloproliferative neoplasms.经典骨髓增殖性肿瘤综述系列介绍
Blood. 2023 Apr 20;141(16):1897-1899. doi: 10.1182/blood.2023019876.
4
A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.骨髓增殖性肿瘤相关并发症的管理聚焦：临床医生视角
Expert Rev Hematol. 2018 Jan;11(1):25-35. doi: 10.1080/17474086.2018.1410433. Epub 2017 Dec 2.
5
[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?].[骨髓增殖性肿瘤的当前诊断标准——需要了解哪些重要内容？]
Harefuah. 2019 Nov;158(11):737-741.
6
Introduction to a review series on myeloproliferative neoplasms.骨髓增殖性肿瘤综述系列介绍
Blood. 2017 Feb 9;129(6):659. doi: 10.1182/blood-2016-12-756619. Epub 2016 Dec 27.
7
Practical management of the haemorrhagic complications of myeloproliferative neoplasms.骨髓增殖性肿瘤出血并发症的实用管理。
Br J Haematol. 2022 Nov;199(3):313-321. doi: 10.1111/bjh.18322. Epub 2022 Jun 20.
8
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.世界卫生组织（WHO）诊断费城染色体阴性骨髓增殖性肿瘤组织学标准的可重复性。
Mod Pathol. 2014 Jun;27(6):814-22. doi: 10.1038/modpathol.2013.196. Epub 2013 Nov 8.
9
Advances in myelodysplastic/myeloproliferative neoplasms.骨髓增生异常/骨髓增殖性肿瘤的进展
Virchows Arch. 2023 Jan;482(1):69-83. doi: 10.1007/s00428-022-03465-7. Epub 2022 Dec 5.
10
Myeloproliferative neoplasms complicated with β-thalassemia: Two case report.骨髓增殖性肿瘤合并β地中海贫血：两例报告。
World J Clin Cases. 2022 Oct 16;10(29):10655-10662. doi: 10.12998/wjcc.v10.i29.10655.

本文引用的文献

1
Evolution of myeloproliferative neoplasms from normal blood stem cells.骨髓增殖性肿瘤从正常血液干细胞的演变。
Haematologica. 2025 Apr 1;110(4):840-849. doi: 10.3324/haematol.2023.283951. Epub 2024 Dec 5.
2
Pathogenesis and management of high molecular risk myeloproliferative neoplasms.高危分子骨髓增殖性肿瘤的发病机制与管理
Haematologica. 2025 Apr 1;110(4):863-876. doi: 10.3324/haematol.2023.283987. Epub 2024 Dec 5.
3
New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?
早期骨髓增殖性肿瘤护理标准的新方法：α干扰素能否改变疾病的自然病程？
Haematologica. 2025 Apr 1;110(4):850-862. doi: 10.3324/haematol.2023.283958. Epub 2024 Oct 24.
4
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.骨髓增殖性肿瘤转化为急性髓系白血病的防治
Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.
5
Identifying disease-modifying potential in myelofibrosis clinical trials.鉴定骨髓纤维化临床试验中的疾病修饰潜力。
Blood. 2024 Oct 17;144(16):1679-1688. doi: 10.1182/blood.2024024220.
6
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.芦可替尼与最佳可用疗法治疗不耐受或对羟基脲耐药的真性红细胞增多症的随机试验。
J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.
7
In utero origin of myelofibrosis presenting in adult monozygotic twins.在成年同卵双胞胎中表现出的骨髓纤维化的宫内起源。
Nat Med. 2022 Jun;28(6):1207-1211. doi: 10.1038/s41591-022-01793-4. Epub 2022 May 30.
8
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.一项干扰素-α与羟基脲治疗 MPN 的随机试验的基因组分析揭示了突变特异性反应。
Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856.
9
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.冰岛对多发性骨髓瘤（iStopMM）进行筛查、治疗或预防：一项针对意义未明的单克隆丙种球蛋白血症的基于人群的筛查研究和随访策略的随机对照试验。
Blood Cancer J. 2021 May 17;11(5):94. doi: 10.1038/s41408-021-00480-w.
10
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.重建骨髓增殖性肿瘤中单个癌细胞的谱系历史和分化轨迹。
Cell Stem Cell. 2021 Mar 4;28(3):514-523.e9. doi: 10.1016/j.stem.2021.02.001. Epub 2021 Feb 22.